BRNS Barinthus Biotherapeutics Plc.
Price (delayed)
$0.76
Market cap
$30.66M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.55
Enterprise value
-$69.74M
vaccitech is a spin-out company from the university of oxford’s jenner institute, one of the oldest and most renowned vaccine research centres in the world. the company has been formed
Highlights
The debt is down by 7% YoY and by 5% QoQ
Barinthus Biotherapeutics's EPS has increased by 19% YoY but it has decreased by 4% from the previous quarter
The net income has grown by 17% YoY but it has contracted by 6% from the previous quarter
Barinthus Biotherapeutics's quick ratio has decreased by 36% YoY
The equity has contracted by 30% YoY and by 18% from the previous quarter
Key stats
What are the main financial stats of BRNS
Market
Valuations
Earnings
Shares outstanding
40.34M
Market cap
$30.66M
Enterprise value
-$69.74M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.24
Price to sales (P/S)
2
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-4.66
Revenue
$14.97M
Gross profit
$14.97M
Operating income
-$67.97M
Net income
-$61.07M
EBIT
-$61.07M
EBITDA
-$53.82M
Free cash flow
-$29.83M
Per share
Balance sheet
Liquidity
EPS
-$1.55
EPS diluted
-$1.55
Free cash flow per share
-$0.76
Book value per share
$3.23
Revenue per share
$0.38
TBVPS
$3.52
Total assets
$160.33M
Total liabilities
$30.19M
Debt
$12.01M
Equity
$130.03M
Working capital
$110.09M
Debt to equity
0.09
Current ratio
8.03
Quick ratio
7.18
Net debt/EBITDA
1.87
Margins
Efficiency
Dividend
EBITDA margin
-359.6%
Gross margin
100%
Net margin
-408%
Operating margin
-454.1%
Return on assets
-33.2%
Return on equity
-39.5%
Return on invested capital
-186.8%
Return on capital employed
-42.2%
Return on sales
-407.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BRNS stock price
How has the Barinthus Biotherapeutics stock price performed over time
Intraday
-5.55%
1 week
-28.3%
1 month
-24.75%
1 year
-67.93%
YTD
-37.09%
QTD
-21.87%
Financial performance
How have Barinthus Biotherapeutics's revenue and profit performed over time
Revenue
$14.97M
Gross profit
$14.97M
Operating income
-$67.97M
Net income
-$61.07M
Gross margin
100%
Net margin
-408%
The operating margin has soared by 96% YoY but it has contracted by 5% from the previous quarter
The net margin has soared by 96% YoY but it is down by 6% QoQ
BRNS's operating income is up by 19% YoY but it is down by 5% from the previous quarter
The net income has grown by 17% YoY but it has contracted by 6% from the previous quarter
Growth
What is Barinthus Biotherapeutics's growth rate over time
Valuation
What is Barinthus Biotherapeutics stock price valuation
P/E
N/A
P/B
0.24
P/S
2
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-4.66
Barinthus Biotherapeutics's EPS has increased by 19% YoY but it has decreased by 4% from the previous quarter
The stock's price to book (P/B) is 38% less than its last 4 quarters average of 0.4
The equity has contracted by 30% YoY and by 18% from the previous quarter
Efficiency
How efficient is Barinthus Biotherapeutics business performance
Barinthus Biotherapeutics's ROS has soared by 96% YoY but it has decreased by 4.1% from the previous quarter
The return on equity has declined by 15% since the previous quarter
Barinthus Biotherapeutics's return on invested capital has decreased by 15% QoQ but it has increased by 13% YoY
BRNS's return on assets is down by 13% since the previous quarter but it is up by 2.9% year-on-year
Dividends
What is BRNS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BRNS.
Financial health
How did Barinthus Biotherapeutics financials performed over time
Barinthus Biotherapeutics's quick ratio has decreased by 36% YoY
The current ratio fell by 36% YoY and by 10% QoQ
The debt is 91% lower than the equity
The equity has contracted by 30% YoY and by 18% from the previous quarter
BRNS's debt to equity is up by 29% year-on-year and by 13% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.